Details
- Autor(en) / Beteiligte
- Titel
- Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts
- Ist Teil von
- Annals of neurology, 2018-12, Vol.84 (6), p.797-811
- Ort / Verlag
- United States: Wiley Subscription Services, Inc
- Erscheinungsjahr
- 2018
- Link zum Volltext
- Quelle
- Wiley Online Library
- Beschreibungen/Notizen
- Levodopa‐induced dyskinesia is a common complication in Parkinson disease. Pathogenic mechanisms include phasic stimulation of dopamine receptors, nonphysiological levodopa‐to‐dopamine conversion in serotonergic neurons, hyperactivity of corticostriatal glutamatergic transmission, and overstimulation of nicotinic acetylcholine receptors on dopamine‐releasing axons. Delay in initiating levodopa is no longer recommended, as dyskinesia development is a function of disease duration rather than cumulative levodopa exposure. We review current and in‐development treatments for peak‐dose dyskinesia but suggest that improvements in levodopa delivery alone may reduce its future prevalence. Ann Neurol 2018;84:797–811
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0364-5134eISSN: 1531-8249DOI: 10.1002/ana.25364Titel-ID: cdi_proquest_miscellaneous_2125299398
- Format
- –
- Schlagworte
- Acetylcholine receptors (nicotinic), Animals, Antiparkinson Agents - adverse effects, Axons, Cortex, Dopamine, Dopamine receptors, Dose-Response Relationship, Drug, Drug Administration Schedule, Dyskinesia, Dyskinesia, Drug-Induced - epidemiology, Dyskinesia, Drug-Induced - etiology, Dyskinesia, Drug-Induced - therapy, Glutamatergic transmission, Humans, Hyperactivity, Levodopa, Levodopa - adverse effects, Movement disorders, Neurodegenerative diseases, Parkinson Disease - drug therapy, Parkinson's disease, Receptors, Serotonin